GT Biopharma GTBP Stock
GT Biopharma Price Chart
GT Biopharma GTBP Financial and Trading Overview
| GT Biopharma stock price | 0.63 USD |
| Previous Close | 0.32 USD |
| Open | 0.31 USD |
| Bid | 0 USD x 1100 |
| Ask | 0 USD x 1000 |
| Day's Range | 0.28 - 0.35 USD |
| 52 Week Range | 0.18 - 3.29 USD |
| Volume | 250.17K USD |
| Avg. Volume | 285.74K USD |
| Market Cap | 13.1M USD |
| Beta (5Y Monthly) | 0.866901 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -3.98 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 3.5 USD |
GTBP Valuation Measures
| Enterprise Value | -7771818 USD |
| Trailing P/E | N/A |
| Forward P/E | -1.0291177 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | N/A |
| Price/Book (mrq) | 0.9884181 |
| Enterprise Value/Revenue | N/A |
| Enterprise Value/EBITDA | N/A |
Trading Information
GT Biopharma Stock Price History
| Beta (5Y Monthly) | 0.866901 |
| 52-Week Change | -88.013% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 3.29 USD |
| 52 Week Low | 0.18 USD |
| 50-Day Moving Average | 0.35 USD |
| 200-Day Moving Average | 1.1 USD |
GTBP Share Statistics
| Avg. Volume (3 month) | 285.74K USD |
| Avg. Daily Volume (10-Days) | 791.53K USD |
| Shares Outstanding | 37.43M |
| Float | 33.48M |
| Short Ratio | 0.51 |
| % Held by Insiders | 5.98% |
| % Held by Institutions | 17.27% |
| Shares Short | 133.32K |
| Short % of Float | 0.36% |
| Short % of Shares Outstanding | 0.36% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor | 1:17 |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | 0% |
| Gross Margin | 0% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -51.23% |
| Return on Equity (ttm) | -101.62% |
Income Statement
| Revenue (ttm) | N/A |
| Revenue Per Share (ttm) | N/A |
| Quarterly Revenue Growth (yoy) | N/A |
| Gross Profit (ttm) | N/A |
| EBITDA | N/A |
| Net Income Avi to Common (ttm) | -15671000 USD |
| Diluted EPS (ttm) | -0.49 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 19.9M USD |
| Total Cash Per Share (mrq) | 0.53 USD |
| Total Debt (mrq) | 147K USD |
| Total Debt/Equity (mrq) | 1.13 USD |
| Current Ratio (mrq) | 4.891 |
| Book Value Per Share (mrq) | 0.354 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -12908000 USD |
| Levered Free Cash Flow (ttm) | -10191500 USD |
Profile of GT Biopharma
| Country | United States |
| State | CA |
| City | Brisbane |
| Address | 8000 Marina Boulevard |
| ZIP | 94005 |
| Phone | 415 919 4040 |
| Website | https://www.gtbiopharma.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 2 |
GT Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology products based on its proprietary Tri-specific Killer Engager (TriKE) fusion protein immune cell engager technology platform. It develops GTB-3550, a single-chain tri-specific recombinant fusion protein conjugate that is in Phase I clinical trial for the treatment of myelodysplastic syndromes, refractory/relapsed acute myeloid leukemia or advanced systemic mastocytosis, and CD33+ malignancies. The company is developing GTB-3650, which is in preclinical studies that target CD33 on the surface of myeloid leukemias; and GTB-5550 that is in preclinical studies for treating patients with B7-H3 positive solid tumors. GT Biopharma, Inc. has a co-development partnership agreement with Altor BioScience Corporation for the clinical development of a 161533 TriKE fusion protein for cancer therapies; and a license agreement with the Regents of the University of Minnesota to develop and commercialize cancer therapies using TriKE technology. The company was formerly known as OXIS International, Inc. and changed its name to GT Biopharma, Inc. in July 2017. GT Biopharma, Inc. was incorporated in 1965 and is based in Brisbane, California.
Q&A For GT Biopharma Stock
What is a current GTBP stock price?
GT Biopharma GTBP stock price today per share is 0.63 USD.
How to purchase GT Biopharma stock?
You can buy GTBP shares on the Tech Market Small exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for GT Biopharma?
The stock symbol or ticker of GT Biopharma is GTBP.
Which industry does the GT Biopharma company belong to?
The GT Biopharma industry is Biotechnology.
How many shares does GT Biopharma have in circulation?
The max supply of GT Biopharma shares is 10.64M.
What is GT Biopharma Price to Earnings Ratio (PE Ratio)?
GT Biopharma PE Ratio is now.
What was GT Biopharma earnings per share over the trailing 12 months (TTM)?
GT Biopharma EPS is -3.98 USD over the trailing 12 months.
Which sector does the GT Biopharma company belong to?
The GT Biopharma sector is Healthcare.
GT Biopharma GTBP included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
| {{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
| US Tech Composite IXIC | 23724.96 USD — |
+0.61
|
9.88B USD — | 23628.82 USD — | 23946.23 USD — | — - | 9.88B USD — |
| US Tech Health Care IXHC | 1115.96 USD — |
+0.87
|
— — | 1099.74 USD — | 1117.62 USD — | — - | — — |
- {{ link.label }} {{link}}